Another study that supported the hypothesis showed that TRAIL-MSCs can induce the apoptosis of TRAIL-CRC-resistant cells and overcome the tumor resistance to TRAIL in clinical treatment, suggesting that MSCs can be used as a carrier for clinical cancer treatment [140]. The gene discussed is TNFSF10; the disease is cancer.